TENAX THERAPEUTICS INC (TENX) Stock Price, Forecast & Analysis
USA - NASDAQ:TENX - US88032L6056 - Common Stock
TENX Key Statistics, Chart & Performance
The current stock price of TENX is 7.35 USD. In the past month the price increased by 9.7%. In the past year, price increased by 49.39%.
TENX Latest News, Press Relases and Analysis
TENX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.76 | 413.38B | ||
| AMGN | AMGEN INC | 15.62 | 183.96B | ||
| GILD | GILEAD SCIENCES INC | 15.15 | 153.97B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25 | 111.28B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.65 | 74.65B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 903.02 | 60.37B | ||
| INSM | INSMED INC | N/A | 41.72B | ||
| NTRA | NATERA INC | N/A | 28.28B | ||
| BIIB | BIOGEN INC | 9.84 | 24.14B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.88 | 21.34B | ||
| INCY | INCYTE CORP | 16.23 | 20.34B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 34.34 | 14.24B |
Related stock screener links
About TENX
Company Profile
Tenax Therapeutics, Inc. is a pharmaceutical company engaged in the development and commercialization of products for cardiovascular and pulmonary diseases. The company is headquartered in Chapel Hill, North Carolina and currently employs 4 full-time employees. The firm is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The firm's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The firm is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The firm has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).
Company Info
TENAX THERAPEUTICS INC
101 Glen Lennox Drive, Suite 300
Chapel Hill NORTH CAROLINA 27560 US
CEO: Anthony DiTonno
Employees: 4
Phone: 19198552100
TENAX THERAPEUTICS INC / TENX FAQ
What does TENAX THERAPEUTICS INC do?
Tenax Therapeutics, Inc. is a pharmaceutical company engaged in the development and commercialization of products for cardiovascular and pulmonary diseases. The company is headquartered in Chapel Hill, North Carolina and currently employs 4 full-time employees. The firm is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The firm's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The firm is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The firm has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).
Can you provide the latest stock price for TENAX THERAPEUTICS INC?
The current stock price of TENX is 7.35 USD. The price increased by 3.52% in the last trading session.
Does TENX stock pay dividends?
TENX does not pay a dividend.
What is the ChartMill technical and fundamental rating of TENX stock?
TENX has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Which stock exchange lists TENX stock?
TENX stock is listed on the Nasdaq exchange.
What sector and industry does TENAX THERAPEUTICS INC belong to?
TENAX THERAPEUTICS INC (TENX) operates in the Health Care sector and the Biotechnology industry.
Who owns TENAX THERAPEUTICS INC?
You can find the ownership structure of TENAX THERAPEUTICS INC (TENX) on the Ownership tab.
TENX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to TENX. When comparing the yearly performance of all stocks, TENX is one of the better performing stocks in the market, outperforming 91.8% of all stocks.
TENX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to TENX. TENX has a great financial health rating, but its profitability evaluates not so good.
TENX Financial Highlights
Over the last trailing twelve months TENX reported a non-GAAP Earnings per Share(EPS) of -1.13. The EPS increased by 93.76% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -29.74% | ||
| ROE | -30.47% | ||
| Debt/Equity | 0 |
TENX Forecast & Estimates
11 analysts have analysed TENX and the average price target is 22.95 USD. This implies a price increase of 212.24% is expected in the next year compared to the current price of 7.35.